

Table S1. Comparison of central serous chorioretinopathy eyes treated with anti-VEGF and without anti-VEGF injection

	With anti-VEGF	Observation	p value
Total number (eyes)	30	31	
Spherical equivalent (D)	0.06 ± 2.17	-0.30 ± 1.05	0.410
Visual acuity (logMAR)			
<i>Baseline (manifest status)</i>	0.26 ± 0.22	0.20 ± 0.22	0.343
<i>Resolution (quiescent status)</i>	0.11 ± 0.14	0.07 ± 0.09	0.137
ONL thickness (μm)			
<i>Baseline (manifest status)</i>	49.5 ± 14.7	54.0 ± 15.2	0.247
<i>Resolution (quiescent status)</i>	65.7 ± 18.3	75.8 ± 20.8	0.047
Choroidal thickness (μm)			
<i>Baseline (manifest status)</i>	370.5 ± 109.7	357.5 ± 88.1	0.777
<i>Resolution (quiescent status)</i>	307.2 ± 97.7	306.0 ± 97.8	0.963
CVI – EC (%)			
<i>Baseline (manifest status)</i>	69.02 ± 2.87	68.73 ± 3.48	0.720
<i>Resolution (quiescent status)</i>	71.59 ± 3.08	71.62 ± 3.22	0.973
CVI – 1500 (%)			
<i>Baseline (manifest status)</i>	69.70 ± 3.03	68.92 ± 6.01	0.610
<i>Resolution (quiescent status)</i>	73.52 ± 3.81	72.02 ± 5.78	0.374

VEGF, vascular endothelial growth factor; logMAR, logarithm of maximum angle resolution; ONL, outer nuclear layer; CVI-EC, choroidal vascularity index of the entire choroid; CVI-1500, choroidal vascularity index of the leaking point $1500\mu\text{m}$ area

Focal laser photocoagulation and photodynamic therapy were excluded from this analysis due to the limited number of cases (4 and 0 eyes, respectively).